Dermata Therapeutics (DRMA) Net Income towards Common Stockholders (2020 - 2026)

Dermata Therapeutics' Net Income towards Common Stockholders history runs 7 years deep, the most recent figure standing at -$1.8 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders rose 38.48% year-over-year to -$1.8 million; the TTM figure through Mar 2026 stood at -$7.1 million (up 57.86% YoY), while the FY2025 annual figure was -$8.3 million, up 59.32% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$1.8 million, up from -$1.9 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was -$1.7 million in Q3 2025, with the low at -$5.0 million in Q3 2024.
• The 5-year median for Net Income towards Common Stockholders is -$2.3 million (2023), against an average of -$2.7 million.
• The sharpest annual moves came in 2024 and 2025: Net Income towards Common Stockholders plunged 189.27% in 2024, then soared 65.98% in 2025.
• Dermata Therapeutics' Net Income towards Common Stockholders stood at -$1.7 million in 2022, then sank by 32.21% to -$2.3 million in 2023, then sank by 96.69% to -$4.5 million in 2024, then jumped by 58.17% to -$1.9 million in 2025, then gained by 0.76% to -$1.8 million in 2026.
• Business Quant data shows DRMA's Net Income towards Common Stockholders at -$1.8 million in Q1 2026, -$1.9 million in Q4 2025, and -$1.7 million in Q3 2025.